Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
PARP抑制剂奥拉帕尼联合PD-L1抑制剂度伐利尤单抗治疗复发性卵巢癌：一项概念验证性II期研究
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-20-0056
Lampert, Erika J; Zimmer, Alexandra; Padget, Michelle; Cimino-Mathews, Ashley; Nair, Jayakumar R; Liu, Yingmiao; Swisher, Elizabeth M; Hodge, James W; Nixon, Andrew B; Nichols, Erin; Bagheri, Mohammad H; Levy, Elliott; Radke, Marc R; Lipkowitz, Stanley; Annunziata, Christina M; Taube, Janis M; Steinberg, Seth M; Lee, Jung-Min
